AC Immune, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, closed an equity offering of 14.3 million of its common shares at a price of USD 3.50 per share successfully.
AC Immune expects the gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, to be approximately USD 50.1 million.
The equity offering was led by BVF Partners L.P., with participation from several existing and new institutional investors including Avidity Partners, Redmile Group, and StemPoint Capital LP.